FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Tag: Arexvy RSV
All
Latest
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults
Johns Hopkins Medicine says further research is needed to better understand the problem and find ways to enhance immune response in this high-risk population.
Read More
Arexvy RSV Vaccine Shows Protection Over Three Seasons
Cumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.
Read More
FDA Expands Approval of Arexvy for Adults Age 50-59
GlaxoSmithKline’s RSV vaccine Arexvy is now available for at-risk adults age 50-59 in addition to those age 60 and older.
Read More
RSV Can Infect Nerve Cells and Enter Spinal Cord
Long thought to only infect the respiratory tract, a new study has found that RSV can infect nerve cells, cause nerve damage, and enter the spinal cord, potentially granting access to the central nervous system.
Read More
Full RSV Vaccination Could Cut Senior Hospitalizations by 91.7%
Respiratory syncytial virus vaccines recently approved for people 60 and older would dramatically reduce the disease’s burden of illness and death if they were widely adopted like annual influenza vaccines, a Yale University study finds.
Read More
Five Pharma Approvals from 2023
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Read More